{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:07:19Z","timestamp":1792076839142,"version":"4.4.0"},"reference-count":279,"publisher":"Elsevier","isbn-type":[{"value":"9780128234686","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.enz.2021.07.002","type":"book-chapter","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T09:41:50Z","timestamp":1634895710000},"page":"315-354","source":"Crossref","is-referenced-by-count":18,"title":["Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs"],"prefix":"10.1016","member":"78","reference":[{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00019053-200826110-00004","article-title":"The impact of influenza on working days lost: a review of the literature","volume":"26","author":"Keech","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"9725","key":"10.1016\/bs.enz.2021.07.002_bb0015","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"issue":"9807","key":"10.1016\/bs.enz.2021.07.002_bb0020","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0025","article-title":"World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis","volume":"12","author":"Kirk","year":"2015","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(14)70767-4","article-title":"Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis","volume":"14","author":"Ahmed","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J. Hepatol."},{"issue":"7446","key":"10.1016\/bs.enz.2021.07.002_bb0045","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"Suppl. 6A","key":"10.1016\/bs.enz.2021.07.002_bb0050","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1016\/S0002-9343(01)01063-4","article-title":"Cost burden of viral respiratory infections: issues for formulary decision makers","volume":"112","author":"Bertino","year":"2002","journal-title":"Am. J. Med."},{"issue":"10049","key":"10.1016\/bs.enz.2021.07.002_bb0055","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/bs.enz.2021.07.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104327","article-title":"Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)\u2014an update on the status","volume":"83","author":"Abd El-Aziz","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"issue":"15","key":"10.1016\/bs.enz.2021.07.002_bb0070","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMra1808246","article-title":"Zika virus infection\u2014after the pandemic","volume":"381","author":"Musso","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb0075","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1473-3099(16)30010-X","article-title":"Zika virus: history of a newly emerging arbovirus","volume":"16","author":"Wikan","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"10174","key":"10.1016\/bs.enz.2021.07.002_bb0080","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41564-018-0296-2","article-title":"Tracking virus outbreaks in the twenty-first century","volume":"4","author":"Grubaugh","year":"2019","journal-title":"Nat. Microbiol."},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14787210.2019.1635009","article-title":"Broad-spectrum antiviral agents: a crucial pandemic tool","volume":"17","author":"Adalja","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/bs.enz.2021.07.002_bb0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","article-title":"Discovery and development of safe-in-man broad-spectrum antiviral agents","volume":"93","author":"Andersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02329-18","article-title":"Origins and evolution of the global RNA virome","volume":"9","author":"Wolf","year":"2018","journal-title":"mBio"},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0105","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00061-19","article-title":"Global organization and proposed megataxonomy of the virus world","volume":"84","author":"Koonin","year":"2020","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003760","article-title":"Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000003","article-title":"Why are RNA virus mutation rates so damn high?","volume":"16","author":"Duffy","year":"2018","journal-title":"PLoS Biol."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4161\/rna.8.2.15013","article-title":"Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity","volume":"8","author":"Denison","year":"2011","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vew014","article-title":"Antiviral drug resistance as an adaptive process","volume":"2","author":"Irwin","year":"2016","journal-title":"Virus Evol."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/v10020076","article-title":"RNA dependent RNA polymerases: insights from structure, function and evolution","volume":"10","author":"Venkataraman","year":"2018","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0135","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.celrep.2017.08.040","article-title":"Crimean-Congo hemorrhagic fever virus suppresses innate immune responses via a ubiquitin and ISG15 specific protease","volume":"20","author":"Scholte","year":"2017","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/v10110641","article-title":"Insight into influenza: a virus cap-snatching","volume":"10","author":"De Vlugt","year":"2018","journal-title":"Viruses"},{"issue":"21","key":"10.1016\/bs.enz.2021.07.002_bb0145","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1128\/JVI.79.21.13373-13384.2005","article-title":"Amino acid residues within conserved domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA cap methyltransferase activity","volume":"79","author":"Li","year":"2005","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0150","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1073\/pnas.0913083107","article-title":"Histidine-mediated RNA transfer to GDP for unique mRNA capping by vesicular stomatitis virus RNA polymerase","volume":"107","author":"Ogino","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.enz.2021.07.002_bb0155","first-page":"137","article-title":"Structure-function relationships among RNA-dependent RNA polymerases","volume":"320","author":"Ng","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/bs.enz.2021.07.002_bb0160","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3389\/fmicb.2019.01945","article-title":"A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses","volume":"10","author":"Jia","year":"2019","journal-title":"Front. Microbiol."},{"issue":"22","key":"10.1016\/bs.enz.2021.07.002_rf0165","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"te Velthuis","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"D1","key":"10.1016\/bs.enz.2021.07.002_rf9000","doi-asserted-by":"crossref","first-page":"D313","DOI":"10.1093\/nar\/gkw1132","article-title":"The SWISS-MODEL Repository\u2014new features and functionality","volume":"45","author":"Bienert","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0170","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0175","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1073\/pnas.0608952104","article-title":"Two proton transfers in the transition state for nucleotidyl transfer catalyzed by RNA- and DNA-dependent RNA and DNA polymerases","volume":"104","author":"Castro","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0180","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nsmb.1540","article-title":"Nucleic acid polymerases use a general acid for nucleotidyl transfer","volume":"16","author":"Castro","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0185","doi-asserted-by":"crossref","first-page":"12943","DOI":"10.3390\/ijms160612943","article-title":"A structural overview of RNA-dependent RNA polymerases from the Flaviviridae family","volume":"16","author":"Wu","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0190","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1099\/jgv.0.000911","article-title":"ICTV virus taxonomy profile: Picornaviridae","volume":"98","author":"Zell","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/MMBR.00012-14","article-title":"Picornavirus morphogenesis","volume":"78","author":"Jiang","year":"2014","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0200","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro1284","article-title":"Host and virus determinants of picornavirus pathogenesis and tropism","volume":"3","author":"Whitton","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0205","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.17.2.465-493.2004","article-title":"Foot-and-mouth disease","volume":"17","author":"Grubman","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0210","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm860","article-title":"Human susceptibility and resistance to Norwalk virus infection","volume":"9","author":"Lindesmith","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb0215","article-title":"Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention","author":"Lemon","year":"2017","journal-title":"J. Hepatol."},{"issue":"9351","key":"10.1016\/bs.enz.2021.07.002_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(03)12162-9","article-title":"The common cold","volume":"361","author":"Heikkinen","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/path.4438","article-title":"Tissue tropism, pathology and pathogenesis of enterovirus infection","volume":"235","author":"Muehlenbachs","year":"2015","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2005.09.015","article-title":"One hundred years of poliovirus pathogenesis","volume":"344","author":"Racaniello","year":"2006","journal-title":"Virology"},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2005.05.032","article-title":"Poliovirus replication and spread in primary neuron cultures","volume":"340","author":"Daley","year":"2005","journal-title":"Virology"},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0240","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.3390\/v7112920","article-title":"Neurotropic enterovirus infections in the central nervous system","volume":"7","author":"Huang","year":"2015","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0245","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nrmicro1769","article-title":"Vaccination against polio should not be stopped","volume":"5","author":"Chumakov","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"issue":"7167","key":"10.1016\/bs.enz.2021.07.002_bb0250","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/bmj.317.7167.1233","article-title":"\"A calculated risk\u201d: the Salk polio vaccine field trials of 1954","volume":"317","author":"Meldrum","year":"1998","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0255","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1136\/jnnp.2003.028530","article-title":"Salk and Sabin: poliomyelitis immunisation","volume":"75","author":"Pearce","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0260","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0265","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/jmv.1890320205","article-title":"Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources","volume":"32","author":"Dunn","year":"1990","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0270","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1128\/JVI.01532-15","article-title":"Sabin vaccine reversion in the field: a comprehensive analysis of Sabin-like poliovirus isolates in Nigeria","volume":"90","author":"Famulare","year":"2016","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/bs.enz.2021.07.002_bb0275","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.1093\/nar\/12.20.7787","article-title":"Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine","volume":"12","author":"Cann","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/bs.enz.2021.07.002_bb0280","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu. Rev. Microbiol."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0285","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0969-2126(97)00261-X","article-title":"Structure of the RNA-dependent RNA polymerase of poliovirus","volume":"5","author":"Hansen","year":"1997","journal-title":"Structure"},{"issue":"17","key":"10.1016\/bs.enz.2021.07.002_bb0290","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1038\/sj.emboj.7600357","article-title":"Structural basis for proteolysis-dependent activation of the poliovirus RNA-dependent RNA polymerase","volume":"23","author":"Thompson","year":"2004","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0295","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biocel.2008.03.019","article-title":"Picornavirus RNA-dependent RNA polymerase","volume":"41","author":"Kok","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"33","key":"10.1016\/bs.enz.2021.07.002_bb0300","doi-asserted-by":"crossref","first-page":"25523","DOI":"10.1074\/jbc.M002671200","article-title":"Poliovirus RNA-dependent RNA polymerase (3Dpol): structural, biochemical, and biological analysis of conserved structural motifs A and B","volume":"275","author":"Gohara","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0305","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jmb.2012.01.049","article-title":"A template RNA entry channel in the fingers domain of the poliovirus polymerase","volume":"417","author":"Kortus","year":"2012","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0310","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1096\/fasebj.10.8.8666162","article-title":"Basic concepts in RNA virus evolution","volume":"10","author":"Domingo","year":"1996","journal-title":"FASEB J."},{"issue":"18","key":"10.1016\/bs.enz.2021.07.002_bb0315","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1021\/bi035212y","article-title":"Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+","volume":"43","author":"Arnold","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/bs.enz.2021.07.002_bb0320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1743-422X-4-44","article-title":"Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase","volume":"4","author":"Freistadt","year":"2007","journal-title":"Virol. J."},{"issue":"7074","key":"10.1016\/bs.enz.2021.07.002_bb0325","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature04388","article-title":"Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population","volume":"439","author":"Vignuzzi","year":"2006","journal-title":"Nature"},{"issue":"Pt. 3","key":"10.1016\/bs.enz.2021.07.002_bb0330","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1099\/vir.0.036988-0","article-title":"The polio-eradication programme and issues of the end game","volume":"93","author":"Minor","year":"2012","journal-title":"J. Gen. Virol."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0335","first-page":"881","article-title":"Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status","volume":"137","author":"John","year":"2013","journal-title":"Indian J. Med. Res."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0340","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.antiviral.2008.04.002","article-title":"A case for developing antiviral drugs against polio","volume":"79","author":"Collett","year":"2008","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0345","first-page":"335","article-title":"Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model","volume":"215","author":"Collett","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0350","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1128\/jvi.66.4.1971-1976.1992","article-title":"Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol","volume":"66","author":"Rodriguez","year":"1992","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/bs.enz.2021.07.002_bb0355","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1021\/jm060872x","article-title":"Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases","volume":"49","author":"Harki","year":"2006","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004733","article-title":"The RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus family","volume":"11","author":"van der Linden","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.enz.2021.07.002_bb0365","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","article-title":"Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance","volume":"8","author":"Beaucourt","year":"2014","journal-title":"Curr. Opin. Virol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0375","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"issue":"49","key":"10.1016\/bs.enz.2021.07.002_bb0380","doi-asserted-by":"crossref","first-page":"46094","DOI":"10.1074\/jbc.C100349200","article-title":"Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin","volume":"276","author":"Maag","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0385","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkg405","article-title":"Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design","volume":"52","author":"Wu","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0390","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.virusres.2004.11.007","article-title":"Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications","volume":"107","author":"Vignuzzi","year":"2005","journal-title":"Virus Res."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0395","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1073\/pnas.1232294100","article-title":"A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity","volume":"100","author":"Pfeiffer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0010011","article-title":"Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice","volume":"1","author":"Pfeiffer","year":"2005","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2006459","article-title":"A speed-fidelity trade-off determines the mutation rate and virulence of an RNA virus","volume":"16","author":"Fitzsimmons","year":"2018","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0410","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/JVI.01574-14","article-title":"Structure-function relationships underlying the replication fidelity of viral RNA-dependent RNA polymerases","volume":"89","author":"Campagnola","year":"2015","journal-title":"J. Virol."},{"issue":"19","key":"10.1016\/bs.enz.2021.07.002_bb0415","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.1128\/JVI.00078-16","article-title":"Poliovirus polymerase Leu420 facilitates RNA recombination and ribavirin resistance","volume":"90","author":"Kempf","year":"2016","journal-title":"J. Virol."},{"issue":"14","key":"10.1016\/bs.enz.2021.07.002_bb0420","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00652-19","article-title":"Picornavirus RNA recombination counteracts error catastrophe","volume":"93","author":"Kempf","year":"2019","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0425","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1128\/JVI.01606-06","article-title":"Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe","volume":"81","author":"Sierra","year":"2007","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0430","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.02420-09","article-title":"Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin","volume":"84","author":"Ferrer-Orta","year":"2010","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001072","article-title":"A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape","volume":"6","author":"Agudo","year":"2010","journal-title":"PLoS Pathog."},{"issue":"24","key":"10.1016\/bs.enz.2021.07.002_bb0440","doi-asserted-by":"crossref","first-page":"12346","DOI":"10.1128\/JVI.01297-08","article-title":"Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin","volume":"82","author":"Arias","year":"2008","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0445","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1128\/JVI.03594-13","article-title":"Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence","volume":"88","author":"Zeng","year":"2014","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0450","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1128\/JVI.00289-14","article-title":"Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice","volume":"88","author":"Meng","year":"2014","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0455","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1128\/JVI.02139-12","article-title":"Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture","volume":"87","author":"Sadeghipour","year":"2013","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0460","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2008.07.033","article-title":"Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis","volume":"382","author":"Agudo","year":"2008","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2013.07.008","article-title":"An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo","volume":"100","author":"Zeng","year":"2013","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0470","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1128\/AAC.01056-07","article-title":"Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues","volume":"52","author":"Graci","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001163","article-title":"Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds","volume":"6","author":"Levi","year":"2010","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0480","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.celrep.2017.10.005","article-title":"Signatures of nucleotide analog incorporation by an RNA-dependent RNA polymerase revealed using high-throughput magnetic tweezers","volume":"21","author":"Dulin","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/bs.enz.2021.07.002_bb0485","doi-asserted-by":"crossref","first-page":"17086","DOI":"10.1038\/nrdp.2017.86","article-title":"Hepatitis E virus infection","volume":"3","author":"Kamar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"17","key":"10.1016\/bs.enz.2021.07.002_bb0490","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0495","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/gutjnl-2016-312670","article-title":"Acute-on-chronic liver failure: an update","volume":"66","author":"Hernaez","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0500","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/hep4.1480","article-title":"Chronic viral hepatitis: current management and future directions","volume":"4","author":"Do","year":"2020","journal-title":"Hepatol. Commun."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0505","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2468-1253(21)00073-X","article-title":"The hunt for a vaccine for hepatitis C virus continues","volume":"6","author":"The Lancet Gastroenterology Hepatology","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0510","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0515","first-page":"316","article-title":"Hepatitis C in a new era: a review of current therapies","volume":"42","author":"Kish","year":"2017","journal-title":"P. T."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0520","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0525","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1073\/pnas.1416266112","article-title":"Functionally conserved architecture of hepatitis C virus RNA genomes","volume":"112","author":"Mauger","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0530","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0535","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0540","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0545","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkp388","article-title":"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)","volume":"65","author":"Kieffer","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039652","article-title":"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"Cento","year":"2012","journal-title":"PLoS One"},{"issue":"51","key":"10.1016\/bs.enz.2021.07.002_bb0555","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0560","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0565","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"issue":"5464","key":"10.1016\/bs.enz.2021.07.002_bb0570","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.288.5464.339","article-title":"The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies","volume":"288","author":"Farci","year":"2000","journal-title":"Science"},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0575","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/13305","article-title":"Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site","volume":"6","author":"Lesburg","year":"1999","journal-title":"Nat. Struct. Biol."},{"issue":"23","key":"10.1016\/bs.enz.2021.07.002_bb0580","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"96","author":"Bressanelli","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0585","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0969-2126(00)80031-3","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"7","author":"Ago","year":"1999","journal-title":"Structure"},{"issue":"6223","key":"10.1016\/bs.enz.2021.07.002_bb0590","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1126\/science.1259210","article-title":"Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase","volume":"347","author":"Appleby","year":"2015","journal-title":"Science"},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0595","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1128\/JVI.00386-12","article-title":"Structure of hepatitis C virus polymerase in complex with primer-template RNA","volume":"86","author":"Mosley","year":"2012","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0600","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/viro.2001.0948","article-title":"A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase","volume":"285","author":"Hong","year":"2001","journal-title":"Virology"},{"issue":"13","key":"10.1016\/bs.enz.2021.07.002_bb0605","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0610","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"issue":"7053","key":"10.1016\/bs.enz.2021.07.002_bb0615","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0620","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/JVI.00201-09","article-title":"Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo","volume":"83","author":"Cuevas","year":"2009","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071039","article-title":"Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis","volume":"8","author":"Ortega-Prieto","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0630","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0635","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0640","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0976-500X.142464","article-title":"Sofosbuvir: a novel treatment option for chronic hepatitis C infection","volume":"5","author":"Bhatia","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb0645","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1128\/AAC.02666-14","article-title":"Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase","volume":"58","author":"Fung","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"41","key":"10.1016\/bs.enz.2021.07.002_bb0650","doi-asserted-by":"crossref","first-page":"29812","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species","volume":"282","author":"Ma","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/bs.enz.2021.07.002_bb0655","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0660","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb0665","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0670","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0675","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep4.1060","article-title":"The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment","volume":"1","author":"Gane","year":"2017","journal-title":"Hepatol. Commun."},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb0680","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/jvh.12405","article-title":"Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy","volume":"22","author":"Hedskog","year":"2015","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0685","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0690","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","article-title":"L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions","volume":"213","author":"Svarovskaia","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"36","key":"10.1016\/bs.enz.2021.07.002_bb0695","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.2174\/092986711798347234","article-title":"Current perspective of HCV NS5B inhibitors: a review","volume":"18","author":"Patil","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0700","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/v7102868","article-title":"Inhibitors of the hepatitis C virus polymerase; mode of action and resistance","volume":"7","author":"Eltahla","year":"2015","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0705","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cld.2011.05.003","article-title":"The HCV NS5B nucleoside and non-nucleoside inhibitors","volume":"15","author":"Membreno","year":"2011","journal-title":"Clin. Liver Dis."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0710","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jmb.2011.10.001","article-title":"An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors","volume":"414","author":"Caillet-Saguy","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0715","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/prot.24154","article-title":"Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase","volume":"81","author":"Davis","year":"2013","journal-title":"Proteins"},{"issue":"17","key":"10.1016\/bs.enz.2021.07.002_bb0720","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3748\/wjg.v13.i17.2416","article-title":"Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy","volume":"13","author":"Le Guillou-Guillemette","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0725","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.02386-13","article-title":"Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors","volume":"58","author":"Di Maio","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb0730","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/bs.enz.2021.07.002_bb0735","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/liv.13685","article-title":"Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection","volume":"38","author":"Asahina","year":"2018","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0740","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/bs.enz.2021.07.002_bb0745","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13305","article-title":"Real-world effectiveness of glecaprevir\/pibrentasvir and ledipasvir\/sofosbuvir for mixed genotype hepatitis C infection: a multicenter pooled analysis in Taiwan","author":"Chiu","year":"2020","journal-title":"J. Viral Hepat."},{"key":"10.1016\/bs.enz.2021.07.002_bb0750","first-page":"3","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0755","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0760","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/bs.enz.2021.07.002_bb0765","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268820000400","article-title":"The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis","volume":"148","author":"Tin Tin Htar","year":"2020","journal-title":"Epidemiol. Infect."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0770","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief history and characterization of enhanced respiratory syncytial virus disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/bs.enz.2021.07.002_bb0775","doi-asserted-by":"crossref","first-page":"107712","DOI":"10.1016\/j.pharmthera.2020.107712","article-title":"Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis","volume":"220","author":"Elawar","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0780","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.6.321","article-title":"Preventing hospitalizations for respiratory syncytial virus infection","volume":"20","author":"Robinson","year":"2015","journal-title":"Paediatr. Child Health"},{"key":"10.1016\/bs.enz.2021.07.002_bb0785","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/CEOR.S60710","article-title":"Respiratory syncytial virus: current and emerging treatment options","volume":"6","author":"Turner","year":"2014","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0790","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Simoes","year":"2018","journal-title":"Infect. Dis. Ther."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0795","doi-asserted-by":"crossref","DOI":"10.1542\/peds.99.3.e7","article-title":"Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database","volume":"99","author":"Law","year":"1997","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0800","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1590\/S1517-83822011000100043","article-title":"Structural analysis of human respiratory syncytial virus p protein: identification of intrinsically disordered domains","volume":"42","author":"Simabuco","year":"2011","journal-title":"Braz. J. Microbiol."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.08.014","article-title":"Structure of the respiratory syncytial virus polymerase complex","volume":"179","author":"Gilman","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0810","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-019-14246-3","article-title":"Cryo-EM structure of the respiratory syncytial virus RNA polymerase","volume":"11","author":"Cao","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0815","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.clinthera.2018.06.014","article-title":"A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children","volume":"40","author":"Nicholson","year":"2018","journal-title":"Clin. Ther."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0820","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0825","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jac\/dky415","article-title":"Respiratory syncytial virus\u2014a dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans","volume":"74","author":"Patel","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/bs.enz.2021.07.002_bb0830","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","author":"Gordon","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2021.07.002_bb0835","doi-asserted-by":"crossref","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0840","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154097","article-title":"Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase","volume":"11","author":"Deval","year":"2016","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/bs.enz.2021.07.002_bb0855","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb0860","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics\u2014a meeting report from the 6th isirv Antiviral Group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb0865","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virusres.2006.01.017","article-title":"Nidovirales: evolving the largest RNA virus genome","volume":"117","author":"Gorbalenya","year":"2006","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb0870","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/jvi.34.3.665-674.1980","article-title":"Coronavirus multiplication strategy. I. Identification and characterization of virus-specified RNA","volume":"34","author":"Stern","year":"1980","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2021.07.002_bb0875","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","article-title":"Hosts and sources of endemic human coronaviruses","volume":"100","author":"Corman","year":"2018","journal-title":"Adv. Virus Res."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb0880","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses","year":"2020","journal-title":"Nat. Microbiol."},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0885","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"issue":"10223","key":"10.1016\/bs.enz.2021.07.002_bb0890","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"7798","key":"10.1016\/bs.enz.2021.07.002_bb0895","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"19","key":"10.1016\/bs.enz.2021.07.002_bb0900","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/bs.enz.2021.07.002_bb0905","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb0910","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/bs.enz.2021.07.002_bb0915","series-title":"Pfizer Letter of Authorization","author":"US Food and Drug Administration","year":"2020"},{"key":"10.1016\/bs.enz.2021.07.002_bb0920","series-title":"Moderna COVID-19 Vaccine Letter of Authorization","author":"US Food and Drug Administration","year":"2020"},{"issue":"27","key":"10.1016\/bs.enz.2021.07.002_bb0925","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0930","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb0935","series-title":"Janssen COVID-19 Vaccine Emergency Use Authorization Letter of Authorization","author":"US Food and Drug Administration","year":"2020"},{"issue":"19","key":"10.1016\/bs.enz.2021.07.002_bb0940","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb0945","series-title":"Recalls and Safety Alerts: Authorization of AstraZeneca COVID-19 Vaccine With English-Only Vial and Carton Labels","author":"Government of Canada","year":"2021"},{"issue":"10269","key":"10.1016\/bs.enz.2021.07.002_bb0950","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.enz.2021.07.002_bb0955","series-title":"Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab","author":"US Food and Drug Administration","year":"2020"},{"key":"10.1016\/bs.enz.2021.07.002_bb0960","series-title":"Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734\u2122)","author":"US Food and Drug Administration","year":"2020"},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb0965","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.enz.2021.07.002_bb0970","doi-asserted-by":"crossref","DOI":"10.1007\/s00705-020-04628-0","article-title":"The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century","author":"da Costa","year":"2020","journal-title":"Arch. Virol."},{"key":"10.1016\/bs.enz.2021.07.002_bb0975","first-page":"57","article-title":"The coronavirus replicase","volume":"287","author":"Ziebuhr","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/bs.enz.2021.07.002_bb0980","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","article-title":"The nonstructural proteins directing coronavirus RNA synthesis and processing","volume":"96","author":"Snijder","year":"2016","journal-title":"Adv. Virus Res."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb0985","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000896","article-title":"Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing","volume":"6","author":"Eckerle","year":"2010","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb0990","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003565","article-title":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.enz.2021.07.002_bb0995","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb1000","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0022-2836(03)00865-9","article-title":"Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage","volume":"331","author":"Snijder","year":"2003","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb1005","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"37","key":"10.1016\/bs.enz.2021.07.002_bb1010","doi-asserted-by":"crossref","first-page":"E3900","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb1015","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nsmb999","article-title":"Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer","volume":"12","author":"Zhai","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb1020","doi-asserted-by":"crossref","first-page":"107774","DOI":"10.1016\/j.celrep.2020.107774","article-title":"Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2","volume":"31","author":"Peng","year":"2020","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb1025","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00291-19","article-title":"Identification and characterization of a human coronavirus 229E nonstructural protein 8-associated RNA 3'-terminal adenylyltransferase activity","volume":"93","author":"Tvarogova","year":"2019","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/bs.enz.2021.07.002_bb1030","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1038\/sj.emboj.7601368","article-title":"A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus","volume":"25","author":"Imbert","year":"2006","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb1035","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/nar\/gkr893","article-title":"The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension","volume":"40","author":"te Velthuis","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/bs.enz.2021.07.002_bb1040","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2021.07.002_bb1045","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","author":"Yin","year":"2020","journal-title":"Science"},{"issue":"6492","key":"10.1016\/bs.enz.2021.07.002_bb1050","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.enz.2021.07.002_bb1055","article-title":"Structural basis for RNA replication by the SARS-CoV-2 polymerase","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/bs.enz.2021.07.002_bb1060","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb1065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"7496","key":"10.1016\/bs.enz.2021.07.002_bb1070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb1075","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/bs.enz.2021.07.002_bb1080","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.bmcl.2015.05.039","article-title":"Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity","volume":"25","author":"Peters","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2\u20133","key":"10.1016\/bs.enz.2021.07.002_bb1085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2005.01.003","article-title":"Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus","volume":"66","author":"Saijo","year":"2005","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb1090","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb1095","article-title":"Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir","volume":"2","author":"Peng","year":"2021","journal-title":"Innovation (N. Y.)"},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb1100","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021946118","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/bs.enz.2021.07.002_bb1105","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2021.07.002_bb1110","article-title":"The nucleotide addition cycle of the SARS-CoV-2 polymerase","author":"Bera","year":"2021","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb1115","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"issue":"7594","key":"10.1016\/bs.enz.2021.07.002_bb1120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"494","key":"10.1016\/bs.enz.2021.07.002_bb1125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau9242","article-title":"Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge","volume":"11","author":"Lo","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb1130","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb1135","doi-asserted-by":"crossref","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"issue":"24","key":"10.1016\/bs.enz.2021.07.002_bb1140","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/bs.enz.2021.07.002_bb1145","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb1150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19-interim WHO solidarity trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb1155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coviro.2021.04.014","article-title":"Remdesivir for the treatment of Covid-19: the value of biochemical studies","volume":"49","author":"Gotte","year":"2021","journal-title":"Curr. Opin. Virol."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb1160","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"396","key":"10.1016\/bs.enz.2021.07.002_bb1165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"541","key":"10.1016\/bs.enz.2021.07.002_bb1170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/bs.enz.2021.07.002_bb1175","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.enz.2021.07.002_bb1180","article-title":"Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","author":"Pruijssers","year":"2020","journal-title":"bioRxiv"},{"issue":"47","key":"10.1016\/bs.enz.2021.07.002_bb1185","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1074\/jbc.AC120.015720","article-title":"Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action","volume":"295","author":"Tchesnokov","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"43","key":"10.1016\/bs.enz.2021.07.002_bb1190","doi-asserted-by":"crossref","first-page":"26946","DOI":"10.1073\/pnas.2012294117","article-title":"Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases","volume":"117","author":"Lo","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/bs.enz.2021.07.002_bb1195","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/bs.enz.2021.07.002_bb1200","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"48","key":"10.1016\/bs.enz.2021.07.002_bb1205","doi-asserted-by":"crossref","first-page":"28115","DOI":"10.1039\/D0CP05297C","article-title":"Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19","volume":"22","author":"Jena","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"Suppl. 4","key":"10.1016\/bs.enz.2021.07.002_bb1210","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/bs.enz.2021.07.002_bb1215","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/bs.enz.2021.07.002_bb1220","series-title":"Global Influenza Strategy 2019\u20132030","author":"World Health Organization","year":"2019"},{"issue":"4 Suppl","key":"10.1016\/bs.enz.2021.07.002_bb1225","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","article-title":"Vaccines: past, present and future","volume":"11","author":"Plotkin","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb1230","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fped.2019.00317","article-title":"Influenza vaccination: effectiveness, indications, and limits in the pediatric population","volume":"7","author":"Mameli","year":"2019","journal-title":"Front. Pediatr."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb1235","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10127","key":"10.1016\/bs.enz.2021.07.002_bb1240","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"issue":"9206","key":"10.1016\/bs.enz.2021.07.002_bb1245","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/bs.enz.2021.07.002_bb1250","series-title":"Influenza Antiviral Medications: Summary for Clinicians","author":"CDC","year":"2020"},{"issue":"7531","key":"10.1016\/bs.enz.2021.07.002_bb1255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature14009","article-title":"Structural insight into cap-snatching and RNA synthesis by influenza polymerase","volume":"516","author":"Reich","year":"2014","journal-title":"Nature"},{"issue":"7531","key":"10.1016\/bs.enz.2021.07.002_bb1260","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature14008","article-title":"Structure of influenza A polymerase bound to the viral RNA promoter","volume":"516","author":"Pflug","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.enz.2021.07.002_bb1265","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","article-title":"Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis","volume":"14","author":"te Velthuis","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.enz.2021.07.002_bb1270","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3389\/fimmu.2018.01581","article-title":"Influenza A virus cell entry, replication, virion assembly and movement","volume":"9","author":"Dou","year":"2018","journal-title":"Front. Immunol."},{"issue":"7240","key":"10.1016\/bs.enz.2021.07.002_bb1275","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature07745","article-title":"The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit","volume":"458","author":"Dias","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.enz.2021.07.002_bb1280","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nsmb.1421","article-title":"The structural basis for cap binding by influenza virus polymerase subunit PB2","volume":"15","author":"Guilligay","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7240","key":"10.1016\/bs.enz.2021.07.002_bb1285","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nature07720","article-title":"Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site","volume":"458","author":"Yuan","year":"2009","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2021.07.002_bb1290","article-title":"Structure and function of the influenza virus transcription and replication machinery","author":"Fodor","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb1295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb1300","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb1305","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.jbc.2021.100486","article-title":"The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor","author":"Todd","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2021.07.002_bb1310","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/bs.enz.2021.07.002_bb1315","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3201\/eid2510.190607","article-title":"Susceptibility of influenza A, B, C, and D viruses to baloxavir","volume":"25","author":"Mishin","year":"2019","journal-title":"Emerg. Infect. Dis."},{"issue":"11","key":"10.1016\/bs.enz.2021.07.002_bb1320","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3201\/eid2511.190757","article-title":"Human-to-human transmission of influenza A (H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019","volume":"25","author":"Takashita","year":"2019","journal-title":"Emerg. Infect. Dis."},{"issue":"515","key":"10.1016\/bs.enz.2021.07.002_bb1325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.enz.2021.07.002_bb1330","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb1335","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb1340","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb1345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.enz.2021.07.002_bb1350","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre-and post-administration of favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antiviral Res."},{"issue":"45","key":"10.1016\/bs.enz.2021.07.002_bb1355","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/bs.enz.2021.07.002_bb1360","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/bs.enz.2021.07.002_bb1365","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"15","key":"10.1016\/bs.enz.2021.07.002_bb1370","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/bs.enz.2021.07.002_bb1375","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/bs.enz.2021.07.002_bb1380","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir. Ther."},{"issue":"7","key":"10.1016\/bs.enz.2021.07.002_bb1385","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","volume":"219","author":"Finberg","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"Web Server issue","key":"10.1016\/bs.enz.2021.07.002_bb1390","doi-asserted-by":"crossref","first-page":"W320","DOI":"10.1093\/nar\/gku316","article-title":"Deciphering key features in protein structures with the new ENDscript server","volume":"42","author":"Robert","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"10.1016\/bs.enz.2021.07.002_bb1395","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."}],"container-title":["The Enzymes","Viral Replication Enzymes and their Inhibitors Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604721000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604721000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:19:03Z","timestamp":1753888743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604721000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780128234686"],"references-count":279,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2021.07.002","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}